KARBE FRANK
Known title: DirectorCIK: 0001276700
KARBE FRANK's purchase track record
KARBE FRANK has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/13/2024 | PHAT | $99K | -44.1% | +34.8% | -1.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PHAT | ▲ Buy | Grant | 24,122 | $0 | 5/19/2026 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 6/3/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 12,500 | $99K | 12/13/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 25,000 | $254K | 5/29/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 5/23/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 9,000 | $0 | 5/25/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.